glp-1 obesity drug news updates How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 Use of diabetes and anti-obesity

In late April 2025, the FDA issued a key update regarding the use of compounded GLP-1 receptor agonists like semaglutide and tirzepatide

This may help combat post-meal sluggishness and support steady energy levels throughout the day.* ENCOURAGE NATURAL FAT BURNING & WEIGHT MANAGEMENT* As appetite balance improves, the body may more effectively tap into stored fat for energy

With incretin-based drugs, much of the reported lean mass loss may not be skeletal muscle, but some is

however, this contradicts established trial data favoring SGLT2 inhibitors for heart failure and should be interpreted cautiously due to possible residual confounding

Fayetteville NC Ozempic Weight Loss Injections at Cape Fear Physical Medicine & Rehab